Comparator supply for NCT03907488
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Sponsor: National Cancer Institute (NCI) (NIH). Phase: PHASE3. Status: Active Not Recruiting. Countries: United States, Canada, Puerto Rico. Last update posted 2026-10-22.
Registry record: https://clinicaltrials.gov/study/NCT03907488.
Canadian-labelled brentuximab vedotin
1 marketed Canadian product(s) from 1 manufacturer(s) contain brentuximab vedotin. Available strengths: 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled dacarbazine
1 marketed Canadian product(s) from 1 manufacturer(s) contain dacarbazine. Available strengths: 600 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled dacarbazine - dtic
1 marketed Canadian product(s) from 1 manufacturer(s) contain dacarbazine. Available strengths: 600 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled doxorubicin hydrochloride
7 marketed Canadian product(s) from 5 manufacturer(s) contain doxorubicin hydrochloride. Available strengths: 150 MG, 2 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled vinblastine sulfate
2 marketed Canadian product(s) from 2 manufacturer(s) contain vinblastine sulfate. Available strengths: 1 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled brentuximab vedotin as a trial comparator?
Yes. We source Canadian-marketed brentuximab vedotin under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT03907488.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1 (431) 588-9055.